3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria:

Histologically or cytologically confirmed advanced solid tumors or lymphoma

Disease considered incurable using standard treatment
ECOG performance status ≤ 2
Life expectancy > 12 weeks
WBC ≥ 3,000/mm^3
Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Total bilirubin normal
AST/ALT ≤ 2.5 times upper limit of normal
Creatinine normal OR creatinine clearance ≥ 60 mL/min
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception prior to and during study treatment
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to 3-AP (Triapine®) and/or gemcitabine hydrochloride
No known glucose-6-phosphate dehydrogenase (G6PD) deficiency
No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements
No pulmonary disease (e.g., dyspnea at rest, supplemental oxygen requirement, or baseline oxygen saturation < 92%)

Prior gemcitabine hydrochloride allowed if given as a standard 30-minute infusion

At least 4 weeks since prior gemcitabine hydrochloride
Patient may have received < 2 lines of chemotherapy in the metastatic setting
No prior 3-AP (Triapine®) or fixed-dose gemcitabine hydrochloride
At least 6 weeks since prior nitrosoureas or mitomycin C
More than 3 weeks since prior radiotherapy
No other concurrent investigational agents
No concurrent combination antiretroviral therapy in HIV-positive patients
No other concurrent anticancer agents or therapies